Functional analysis of the novel modulator of gamma secretase

最近的报告显示，460万日本人患有痴呆症，超过400万人患有轻度认知障碍。这一病因学研究的巨大数字让我们感到惊讶，在日本和老龄化不断增加的国家，建立阿尔茨海默氏病的基础疗法是非常必要的。许多证据已经意识到，淀粉样β蛋白的增加是罪魁祸首。小鼠体内Abeta产生的遗传调节模拟了AD的大脑病理，并恶化了认知功能。本研究鉴定了一种新的Abeta产生酶的调节蛋白。已识别的调制器特定于Abeta生产，而不是另一种关键的Notch生产。我们还证实了新型调节剂的转基因小鼠减少了小鼠大脑中Abeta的产生。这些发现表明，所识别的调节剂是AD的治疗靶点。

The recent report revealed that 4.6 million Japanese suffer with dementia and more than 4 million, with minimal cognitive impairment. This huge number by this etiological research surprised us and the establishment of fundamental therapeutics of Alzheimer's disease is strongly desired in Japan as well as in the countries where the aged are increasing. A lot of evidence have realized that the increase in amyloid beta is a culprit. The genetic modulation of Abeta production in mice mimics the AD brain pathology and deteriorates the cognitive function. This study identified the novel modulating protein of Abeta producing enzyme. The identified modulator is specific to Abeta production, not to another pivotal Notch production. We also confirmed that transgenic mouse of the novel modulator decreased Abeta production in the mouse brain. These findings suggest that the identified modulator is a therapeutic target of AD.